Therapeutic potential of protein and adjuvant vaccinations on tumour growth.
Over 90% of cervical cancers are associated with HPV infection, the commonest being the HPV-16 subtype. Two early viral genes, E6 and 7, play major roles in the development and maintenance of the malignant phenotype. The vaccine potential of a recombinant HPV16 E7 protein was examined in two murine models of E7-expressing tumours. Formulations including the immunostimulants MPL and QS21 induced therapeutically active immune responses leading to regression of pre-established TC1 tumour lesions, associated with induction of IgG antibodies, lymphoproliferation and CTL. Our data provide a clear incentive to investigate the clinical application of this approach in cancer immunotherapy.
SmithKline Beecham Biologicals, R&D, Preclinical Immunology, Rue de 1'Institut 89, B-1330, Rixensart, Belgium. catherine.gerard@sbbio.be
C M
CM
Gérard
N
N
Baudson
K
K
Kraemer
C
C
Bruck
N
N
Garçon
Y
Y
Paterson
Z K
ZK
Pan
D
D
Pardoll
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D000912:Antibodies, Neoplasm / Q000096:biosynthesis; D000914:Antibodies, Viral / Q000096:biosynthesis; D019496:Cancer Vaccines / Q000235:genetics / Q000627:therapeutic use*; D005260:Female; D007074:Immunoglobulin G / Q000096:biosynthesis; D066298:In Vitro Techniques; D008175:Lung Neoplasms / Q000556:secondary; D008213:Lymphocyte Activation; D051379:Mice; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D009856:Oncogene Proteins, Viral / Q000235:genetics / Q000276:immunology; D027383:Papillomaviridae; D050725:Papillomavirus E7 Proteins; D030361:Papillomavirus Infections / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014412:Tumor Virus Infections / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D014614:Vaccines, Synthetic / Q000235:genetics / Q000627:therapeutic use; D014765:Viral Vaccines / Q000235:genetics / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D000912:Antibodies, Neoplasm; D000914:Antibodies, Viral; D019496:Cancer Vaccines; D007074:Immunoglobulin G; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D014614:Vaccines, Synthetic; D014765:Viral Vaccines; C059731:oncogene protein E7, Human papillomavirus type 16